Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Exact Sciences Corporation, Recursion Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Exact Sciences Corporation, Recursion Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Exact Sciences Corporation, Recursion Pharmaceuticals and Inc.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Latest Biotechnology and Exact Sciences Corporation, Recursion Pharmaceuticals, Inc. Stock News

As of March 5, 2026, Exact Sciences Corporation had a $19.7 billion market capitalization, compared to the Biotechnology median of $270.5 million. Exact Sciences Corporation’s stock is up 1.9% in 2026, up 0.1% in the previous five trading days and up 111.81% in the past year.

Currently, Exact Sciences Corporation does not have a price-earnings ratio. Exact Sciences Corporation’s trailing 12-month revenue is $3.2 billion with a -6.4% net profit margin. Year-over-year quarterly sales growth most recently was 23.1%. Analysts expect adjusted earnings to reach $1.135 per share for the current fiscal year. Exact Sciences Corporation does not currently pay a dividend.

As of March 5, 2026, Recursion Pharmaceuticals, Inc. had a $1.9 billion market cap, putting it in the 54th percentile of all stocks. Recursion Pharmaceuticals, Inc.’s stock is down 15.4% in 2026, down 5.7% in the previous five trading days and down 45.29% in the past year.

Currently, Recursion Pharmaceuticals, Inc. does not have a price-earnings ratio. Recursion Pharmaceuticals, Inc.’s trailing 12-month revenue is $74.7 million with a -863.4% net profit margin. Year-over-year quarterly sales growth most recently was 688.9%. Analysts expect adjusted earnings to reach $-0.986 per share for the current fiscal year. Recursion Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Exact Sciences Corporation, Recursion Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Exact Sciences Corporation, Recursion Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Exact Sciences Corporation, Recursion Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
Exact Sciences Corporation	EXAS	F
Recursion Pharmaceuticals, Inc.	RXRX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Exact Sciences Corporation has a Value Score of 5, which is Ultra Expensive. Recursion Pharmaceuticals, Inc. has a Value Score of 11, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Exact Sciences Corporation, Recursion Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Exact Sciences Corporation, Recursion Pharmaceuticals or Inc. is the better investment when it comes to value.

Exact Sciences Corporation, Recursion Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Exact Sciences Corporation	EXAS	B
Recursion Pharmaceuticals, Inc.	RXRX	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Exact Sciences Corporation has a Quality Score of 66, which is Strong. Recursion Pharmaceuticals, Inc. has a Quality Score of 25, which is Weak.

The Quality Grade Winner: Exact Sciences Corporation

As you can clearly see from the Quality Grade breakdown above, Exact Sciences Corporation has a better overall quality grade than Recursion Pharmaceuticals, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Exact Sciences Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Exact Sciences Corporation, Recursion Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Exact Sciences Corporation	EXAS	A
Recursion Pharmaceuticals, Inc.	RXRX	F

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Exact Sciences Corporation has a Momentum Score of 88, which is Very Strong. Recursion Pharmaceuticals, Inc. has a Momentum Score of 11, which is Very Weak.

The Momentum Grade Winner: Exact Sciences Corporation

As you can clearly see from the Momentum Grade breakdown above, Exact Sciences Corporation is considered to have stronger momentum compared to Recursion Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Exact Sciences Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Exact Sciences Corporation, Recursion Pharmaceuticals and Inc. Grades

In addition to Momentum, Value and Quality, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Exact Sciences Corporation, Recursion Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Exact Sciences Corporation, Recursion Pharmaceuticals or Inc. Stock?

Overall, Exact Sciences Corporation stock has a Value Score of 5, Momentum Score of 88 and Quality Score of 66.

Recursion Pharmaceuticals, Inc. stock has a Value Score of 11, Momentum Score of 11 and Quality Score of 25.

Comparing Exact Sciences Corporation, Recursion Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.